AUTHOR=De Castelbajac Thalia , Aiello Kiara , Arenas Celia Garcia , Svingen Terje , Ramhøj Louise , Zalko Daniel , Barouki Robert , Vanhaecke Tamara , Rogiers Vera , Audebert Marc , Oelgeschlaeger Michael , Braeuning Albert , Blanc Etienne , Tal Tamara , Rüegg Joëlle , Fritsche Ellen , Marx-Stoelting Philip , Rivière Gilles TITLE=Innovative tools and methods for toxicity testing within PARC work package 5 on hazard assessment JOURNAL=Frontiers in Toxicology VOLUME=5 YEAR=2023 URL=https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2023.1216369 DOI=10.3389/ftox.2023.1216369 ISSN=2673-3080 ABSTRACT=

New approach methodologies (NAMs) have the potential to become a major component of regulatory risk assessment, however, their actual implementation is challenging. The European Partnership for the Assessment of Risks from Chemicals (PARC) was designed to address many of the challenges that exist for the development and implementation of NAMs in modern chemical risk assessment. PARC’s proximity to national and European regulatory agencies is envisioned to ensure that all the research and innovation projects that are initiated within PARC agree with actual regulatory needs. One of the main aims of PARC is to develop innovative methodologies that will directly aid chemical hazard identification, risk assessment, and regulation/policy. This will facilitate the development of NAMs for use in risk assessment, as well as the transition from an endpoint-based animal testing strategy to a more mechanistic-based NAMs testing strategy, as foreseen by the Tox21 and the EU Chemical’s Strategy for Sustainability. This work falls under work package 5 (WP5) of the PARC initiative. There are three different tasks within WP5, and this paper is a general overview of the five main projects in the Task 5.2 ‘Innovative Tools and methods for Toxicity Testing,’ with a focus on Human Health. This task will bridge essential regulatory data gaps pertaining to the assessment of toxicological prioritized endpoints such as non-genotoxic carcinogenicity, immunotoxicity, endocrine disruption (mainly thyroid), metabolic disruption, and (developmental and adult) neurotoxicity, thereby leveraging OECD’s and PARC’s AOP frameworks. This is intended to provide regulatory risk assessors and industry stakeholders with relevant, affordable and reliable assessment tools that will ultimately contribute to the application of next-generation risk assessment (NGRA) in Europe and worldwide.